Sharescart Research Club logo
Products
Research
Tools
About
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel
Apollo Green₹ 72 (28.6%)ASK Investment₹ 895 (-3.2%)AVPL ₹ 49 (0%)Bootes Impex₹ 775 (-8.8%)CIAL ₹ 442 (-0.5%)CSK ₹ 254 (-3.1%)ESDS Software₹ 478 (2.8%)Garuda Aerospace₹ 468 (-2.1%)Goodluck Defence₹ 385 (16%)Hero Motors₹ 325 (0%)Hinduja Leyland₹ 248 (0%)ICL Fincorp₹ 25 (0%)Incred Holdings₹ 154 (2.7%)Kineco Limited₹ 3285 (0%)Lava ₹ 60 (15.4%)Market Simplified₹ 26 (-7.1%)Matrix Gas₹ 12 (-20%)Motilal Oswal₹ 12.25 (-2%)MSEI ₹ 6.35 (-2.3%)NCDEX ₹ 368 (-1.6%)NSE ₹ 1985 (-2%)Onix Renewable₹ 68 (21.4%)OYO ₹ 23 (-4.2%)OYO Assets₹ 9.25 (-7%)Philips India₹ 1250 (0%)Polymatech Electronics₹ 56 (-3.4%)SBI Mutual₹ 768 (-0.9%)Taparia Tools₹ 6050 (0%)VCI Chemical₹ 64 (0%)Zepto ₹ 40 (-4.8%)

15 Days Price Change

Onyx Biotec IPO

Closing In

  • days
  • Hours
  • Minutes
  • Seconds

WEBSITE Inc. Year: 2005 Industry: Pharmaceuticals & Drugs Listed Page

Profile
Issue Size --
Profile
Price Range 58  to  61 per share
Profile
Min Investment ₹61
Profile
Lot Size 1
Profile
Face Value ₹10
Profile
Draft Prospectus --
Invest Before the IPO Goes Live

Buy unlisted shares early and participate in the growth before public listing.

Profile
  • Basic Info
  • IPO Tentative Timetable
  • IPO Lot Size
  • Subscription Status
  • Financials
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Ratios
  • Growth Rates
  • Other info

Overview

Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company specializing in the production of sterile water for injections. The company manufactures Sterile Water for Injections and operates as a contract manufacturer, offering a diverse range of dry powder injections and dry syrups for both domestic and international markets. Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company specializing in the production of sterile water for injections. The company manufactures Sterile Water for Injections and operates as a contract manufacturer, offering a diverse range of dry powder injections and dry syrups for both domestic and international markets. Read More

Basic Info

Face Value 10 per share

Price 58  to  61 per share

P/E (x) 18.5

Sales( Cr.) 62

PAT( Cr.) 5

EPS 3.3

Draft Prospectus --

Exchange NSE-SME

Promoter

Company Promoters

Sanjay Jain Naresh Kumar Fateh Pal Singh.

Pre Issue Share Holding 100%

Post Issue Share Holding 38.96%

Listing Details:

Listing Price: 54.05

Listing Gain: -12.86%

Current Price: 39

Gain On Issue: 39 | 0%

GMP: --

GMP %: -- %

IPO Tentative Timetable

Opening Date Nov 13, 2024
Closing Date Nov 18, 2024
Allotment Nov 19, 2024
Refund Nov 20, 2024
Delivery of Shares Nov 20, 2024
Listing Date Nov 21, 2024

IPO Lot Size

Application Lots Shares Amount
Retail (Min) 1 2000 122,000
Retail (Max) 1 2000 122,000
S-HNI (Min) 2 4000 244,000
S-HNI (Max) 8 16000 976,000
B-HNI (Min) 9 18000 1,098,000

Objective of the Issue

1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use. 2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections. 3. Prepayment or repayment of all or a portion of certain loans availed by the Company. 4. General Corporate Purposes.

Issue

Category Nos Bid Bid (x)
QIB 2405000 78138450 32.5x
NII 721500 434963490 602.9x
Retail 1683500 199090710 118.3x
EMP 0 0 0x
Total 4810000 952380000 198x

Net Sales (in cr.)

Total Income (in cr.)

Operating Profit (in cr.)

Net Profit (in cr.)

Shareholder Funds (in cr.)

Total Assets (in cr.)

Onyx Biotec Profit & Loss

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 45 39 54 62
Other Income 0 0 0 1
Total Income 45 40 54 63
Total Expenditure 39 35 45 52
Operating Profit 6 5 9 12
Interest 1 1 2 2
Depreciation 1 1 2 3
Exceptional Income / Expenses 0 0 0 0
Profit Before Tax 4 3 4 6
Provision for Tax 0 1 1 2
Profit After Tax 3 2 4 5
Adjustments 0 0 0 0
Profit After Adjustments 3 2 4 5
Adjusted Earnings Per Share 2.8 1.6 2.7 2.7

Onyx Biotec Balance Sheet

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 16 18 25 56
Minority's Interest 0 0 0 0
Borrowings 9 18 24 7
Other Non-Current Liabilities 2 2 3 3
Total Current Liabilities 10 20 23 26
Total Liabilities 37 59 74 91
Fixed Assets 17 43 43 41
Other Non-Current Assets 5 2 1 1
Total Current Assets 14 15 30 49
Total Assets 37 59 74 91

Onyx Biotec Cash Flow

#(Fig in Cr.) Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 1
Cash Flow from Operating Activities 0 6 2 1
Cash Flow from Investing Activities -6 -23 -3 1
Cash Flow from Financing Activities 5 16 3 5
Net Cash Inflow / Outflow -0 -0 1 7
Closing Cash & Cash Equivalent 0 0 1 9

Onyx Biotec Ratios

# Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 2.84 1.56 2.73 2.73
CEPS(Rs) 4.07 2.83 4.13 4.41
DPS(Rs) 0 0 0 0
Book NAV/Share(Rs) 13.87 15.42 18.98 30.68
Core EBITDA Margin(%) 12.87 11.37 15.61 16.74
EBIT Margin(%) 9.9 7.91 12.37 13.71
Pre Tax Margin(%) 8.46 6.45 8.35 10.46
PAT Margin (%) 7.47 4.67 6.76 8
Cash Profit Margin (%) 10.7 8.45 10.24 12.92
ROA(%) 9.1 3.86 5.47 5.99
ROE(%) 20.47 10.67 16.71 12.25
ROCE(%) 15.52 8.21 12.85 13.68
Receivable days 68.49 62.37 69.43 104.89
Inventory Days 24.84 43.36 52.4 74.24
Payable days 59.4 97.57 105.74 142.32
PER(x) 0 0 0 21.23
Price/Book(x) 0 0 0 1.89
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.4 0.89 0.79 1.76
EV/Core EBITDA(x) 3.08 7.61 5.01 9.45
Net Sales Growth(%) 0 -11.99 36.14 15.26
EBIT Growth(%) 0 -29.75 112.96 27.78
PAT Growth(%) 0 -44.98 97.04 36.31
EPS Growth(%) 0 -44.98 74.57 0.15
Debt/Equity(x) 0.75 1.61 1.22 0.22
Current Ratio(x) 1.44 0.72 1.31 1.91
Quick Ratio(x) 1.17 0.42 0.91 1.29
Interest Cover(x) 6.86 5.43 3.08 4.21
Total Debt/Mcap(x) 0 0 0 0.12

Sihora Industries Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 15% 11% 0% 0%
Operating Profit CAGR 33% 26% 0% 0%
PAT CAGR 25% 19% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -19% NA% NA% NA%
ROE Average 12% 13% 15% 15%
ROCE Average 14% 12% 13% 13%

Company Contact Information

Onyx Biotec Ltd.

Village Bir Plassi Near Sainimajraropar Nalagarh Road

IPO Lead Manager(s)

Onyx Biotec Ltd.

Horizon Management Pvt Ltd.

Registrar Info

Onyx Biotec Ltd.

Frequently Asked Questions

All You Need To Know About IPO

When you leave without vesting, generally unvested ESOPs are cancelled. Vested ESOPs usually can be exercised after you depart, often within 3 to 6 months, depending on the company's ESOP plan.

For companies listed on a stock exchange, you can sell the shares any time after you exercise the ESOP option and the shares are in your demat account. If the company is unlisted or otherwise a startup, you can only sell the shares if and when the company announces a buyback or has a process for secondary sales.

Whenever you exercised your options to hold shares, you entered into a market risk situation, and if the valuation of the company drops, so do the shares.

Yes. ESOPs are valuable to the employer in that the employer is able to retain the best talent, align employee interests with company goals, and preserve cash while rewarding performance.

Wealth Icon
Don’t Miss Out on Unlisted Shares

Open your account today and gain instant access to top unlisted shares and pre-IPO opportunities.

whatsapp

Error!